COSCIENS Biopharma Inc
TSX:CSCI

Watchlist Manager
COSCIENS Biopharma Inc Logo
COSCIENS Biopharma Inc
TSX:CSCI
Watchlist
Price: 2.9 CAD -2.03% Market Closed
Market Cap: 9.4m CAD

COSCIENS Biopharma Inc
PP&E Net

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

COSCIENS Biopharma Inc
PP&E Net Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Net CAGR 3Y CAGR 5Y CAGR 10Y
COSCIENS Biopharma Inc
TSX:CSCI
PP&E Net
$9.9m
CAGR 3-Years
362%
CAGR 5-Years
118%
CAGR 10-Years
42%
Theratechnologies Inc
TSX:TH
PP&E Net
$892k
CAGR 3-Years
-33%
CAGR 5-Years
-25%
CAGR 10-Years
24%
Repare Therapeutics Inc
NASDAQ:RPTX
PP&E Net
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
PP&E Net
$84.8m
CAGR 3-Years
114%
CAGR 5-Years
54%
CAGR 10-Years
N/A
X
Xenon Pharmaceuticals Inc
NASDAQ:XENE
PP&E Net
$15.8m
CAGR 3-Years
9%
CAGR 5-Years
33%
CAGR 10-Years
22%
Spectral Medical Inc
TSX:EDT
PP&E Net
CA$524k
CAGR 3-Years
-16%
CAGR 5-Years
-14%
CAGR 10-Years
3%
No Stocks Found

COSCIENS Biopharma Inc
Glance View

Market Cap
9.2m CAD
Industry
Biotechnology

COSCIENS Biopharma Inc is a CA-based company operating in Biotechnology industry. The company is headquartered in Toronto, Ontario. COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The firm is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.

CSCI Intrinsic Value
HIDDEN
Show

See Also

What is COSCIENS Biopharma Inc's PP&E Net?
PP&E Net
9.9m USD

Based on the financial report for Sep 30, 2025, COSCIENS Biopharma Inc's PP&E Net amounts to 9.9m USD.

What is COSCIENS Biopharma Inc's PP&E Net growth rate?
PP&E Net CAGR 10Y
42%

Over the last year, the PP&E Net growth was -16%. The average annual PP&E Net growth rates for COSCIENS Biopharma Inc have been 362% over the past three years , 118% over the past five years , and 42% over the past ten years .

Back to Top